{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:48:01Z","timestamp":1790754481216,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression. Next, the result of the modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) (cut-off \u22653), the presence of high-volume bone metastases (as defined by CHAARTED criteria), hemoglobin (Hb) (cut off &lt; 13.2 g\/dl), Gleason score \u22658, and presence of\u00a0visceral metastases were combined into the Metastasized Prostate Cancer Survival Score (MeProCSS). Patients were then stratified into three prognostic groups. Their OS was assessed by Kaplan\u2013Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS for the overall cohort (\n                      <jats:italic>n<\/jats:italic>\n                      = 153) and the first-line cohort (\n                      <jats:italic>n<\/jats:italic>\n                      = 83) was 18 and 21.5 months, respectively. In multivariable analysis, high-volume bone metastases and Hb levels below the norm were significant predictors of shorter OS in the total cohort. The MeProCSS demonstrated an area under curve (AUC) of 0.837 in the overall cohort and 0.946 in first-line cohort. Kaplan\u2013Meier analysis revealed a significant association between lower MeProCSS and longer OS in both the overall (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) and first-line (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.035) cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MeProCSS, consisting of routinely collected parameters prior to the start of chemotherapy, seems to effectively stratify patients with mCRPC into risk groups based on their metastatic burden, nutritional and inflammatory status. This model may guide treatment decisions and reveal a potentially often underestimated or overlooked urgency for additional measures as supportive palliative care in mCRPC patients. Further large and prospective studies are necessary for validation of MeProCSS\u2014also in other systemic PC therapy regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04389-2","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:02:32Z","timestamp":1737982952000},"page":"2063-2072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort"],"prefix":"10.1007","volume":"57","author":[{"given":"Felix","family":"Steffens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Hetjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Moharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Patroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stefan","family":"Worst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Friedrich","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice Stephan","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Neuberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"3","key":"4389_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4389_CR2","unstructured":"Cancer Stat Facts 2024 : Prostate cancer. Retrieved 10.10.2024]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"4389_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","volume":"1096","author":"A Mansinho","year":"2018","unstructured":"Mansinho A et al (2018) Castration-resistant prostate cancer: mechanisms, targets and treatment. Adv Exp Med Biol 1096:117\u2013133","journal-title":"Adv Exp Med Biol"},{"issue":"10024","key":"4389_CR4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u201377","journal-title":"Lancet"},{"issue":"11","key":"4389_CR5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE et al (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"10","key":"4389_CR6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.acuro.2020.08.001","volume":"44","author":"MJ Donate-Moreno","year":"2020","unstructured":"Donate-Moreno MJ et al (2020) Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer. Actas Urol Esp (Engl Ed) 44(10):692\u2013700","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"6","key":"4389_CR7","doi-asserted-by":"crossref","first-page":"600 e9","DOI":"10.1016\/j.urolonc.2019.11.005","volume":"38","author":"J Stangl-Kremser","year":"2020","unstructured":"Stangl-Kremser J et al (2020) Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol. 38(6):600 e9-600 e15","journal-title":"Urol Oncol."},{"issue":"2","key":"4389_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 86(2):164\u2013182","journal-title":"Eur Urol."},{"issue":"1","key":"4389_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","volume":"16","author":"AJ Armstrong","year":"2010","unstructured":"Armstrong AJ et al (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1):203\u201311","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4389_CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clgc.2019.06.012","volume":"17","author":"J Stangl-Kremser","year":"2019","unstructured":"Stangl-Kremser J et al (2019) Prevalence and prognostic value of the polymorphic variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. Clin Genitourin Cancer 17(5):389\u2013394","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"4389_CR11","first-page":"1302","volume":"25","author":"Q Wang","year":"2021","unstructured":"Wang Q et al (2021) Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci 25(3):1302\u20131310","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"4389_CR12","doi-asserted-by":"crossref","first-page":"e2544","DOI":"10.1097\/MD.0000000000002544","volume":"95","author":"X Yin","year":"2016","unstructured":"Yin X et al (2016) Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore) 95(3):e2544","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"4389_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040773","volume":"13","author":"K Ando","year":"2021","unstructured":"Ando K et al (2021) Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers (Basel) 13(4):1","journal-title":"Cancers (Basel)"},{"key":"4389_CR14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"RD Dolan","year":"2018","unstructured":"Dolan RD et al (2018) The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol 132:130\u2013137","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"4389_CR15","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00345-018-2590-2","volume":"37","author":"T Okamoto","year":"2019","unstructured":"Okamoto T et al (2019) Impact of nutritional status on the prognosis of patients with metastatic hormone-naive prostate cancer: a multicenter retrospective cohort study in Japan. World J Urol 37(9):1827\u20131835","journal-title":"World J Urol"},{"issue":"7","key":"4389_CR16","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s00432-022-04220-w","volume":"149","author":"M Neuberger","year":"2023","unstructured":"Neuberger M et al (2023) Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol 149(7):3371\u20133381","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"4389_CR17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u201346","journal-title":"N Engl J Med"},{"issue":"3","key":"4389_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N et al (2019) Inflammation and cancer. Ann Afr Med 18(3):121\u2013126","journal-title":"Ann Afr Med"},{"issue":"12","key":"4389_CR19","first-page":"3877","volume":"10","author":"D Dai","year":"2018","unstructured":"Dai D et al (2018) Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. Am J Transl Res 10(12):3877\u20133886","journal-title":"Am J Transl Res"},{"issue":"5","key":"4389_CR20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"key":"4389_CR21","doi-asserted-by":"crossref","first-page":"1052943","DOI":"10.3389\/fmed.2022.1052943","volume":"9","author":"W Qi","year":"2022","unstructured":"Qi W et al (2022) Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis. Front Med (Lausanne) 9:1052943","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"4389_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1940-6207.CAPR-23-0423","volume":"17","author":"L Antonucci","year":"2024","unstructured":"Antonucci L, Karin M (2024) The Past and Future of Inflammation as a Target to Cancer Prevention. Cancer Prev Res (Phila) 17(4):141\u2013155","journal-title":"Cancer Prev Res (Phila)"},{"issue":"7","key":"4389_CR23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pros.23969","volume":"80","author":"Y Yamada","year":"2020","unstructured":"Yamada Y et al (2020) Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate 80(7):559\u2013569","journal-title":"Prostate"},{"issue":"6b","key":"4389_CR24","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1111\/bju.12531","volume":"114","author":"P Nuhn","year":"2014","unstructured":"Nuhn P et al (2014) Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int 114(6b):E11\u2013E17","journal-title":"BJU Int"},{"key":"4389_CR25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fphar.2016.00376","volume":"7","author":"C Lolli","year":"2016","unstructured":"Lolli C et al (2016) Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front Pharmacol 7:376","journal-title":"Front Pharmacol"},{"key":"4389_CR26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69","journal-title":"Nutr J"},{"issue":"19","key":"4389_CR27","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1002\/cam4.4205","volume":"10","author":"J Pan","year":"2021","unstructured":"Pan J et al (2021) Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. Cancer Med 10(19):6697\u20136704","journal-title":"Cancer Med"},{"issue":"2","key":"4389_CR28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/01635581.2021.1884731","volume":"74","author":"L Cavka","year":"2022","unstructured":"Cavka L et al (2022) Nutritional Status and Health-Related Quality of Life in Men with Advanced Castrate-Resistant Prostate Cancer. Nutr Cancer 74(2):472\u2013481","journal-title":"Nutr Cancer"},{"issue":"7","key":"4389_CR29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/cncr.33341","volume":"127","author":"EM Sohlberg","year":"2021","unstructured":"Sohlberg EM et al (2021) Laboratory-wide association study of survival with prostate cancer. Cancer 127(7):1102\u20131113","journal-title":"Cancer"},{"issue":"4","key":"4389_CR30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clgc.2013.04.020","volume":"11","author":"A Linton","year":"2013","unstructured":"Linton A et al (2013) Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 11(4):423\u201330","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"4389_CR31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/pcan.2011.60","volume":"15","author":"K Shafique","year":"2012","unstructured":"Shafique K et al (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 15(2):195\u2013201","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"4389_CR32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00280-023-04592-x","volume":"93","author":"S Goktas Aydin","year":"2024","unstructured":"Goktas Aydin S et al (2024) Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemother Pharmacol 93(1):71\u201378","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4389_CR33","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.21873\/anticanres.15668","volume":"42","author":"M Neuberger","year":"2022","unstructured":"Neuberger M et al (2022) Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy. Anticancer Res 42(4):1911\u20131918","journal-title":"Anticancer Res"},{"issue":"19","key":"4389_CR34","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","volume":"20","author":"O Smaletz","year":"2002","unstructured":"Smaletz O et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20(19):3972\u201382","journal-title":"J Clin Oncol"},{"issue":"15","key":"4389_CR35","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/pros.24419","volume":"82","author":"SC Yazgan","year":"2022","unstructured":"Yazgan SC et al (2022) Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. Prostate 82(15):1456\u20131461","journal-title":"Prostate"},{"issue":"5","key":"4389_CR36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/onco.13727","volume":"26","author":"JT Brown","year":"2021","unstructured":"Brown JT et al (2021) Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors. Oncologist 26(5):397\u2013405","journal-title":"Oncologist"},{"issue":"5","key":"4389_CR37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000519358","volume":"107","author":"DL Draeger","year":"2023","unstructured":"Draeger DL et al (2023) Prediction of treatment response and survival with chemotherapy for metastatic penile cancer by the modified Glasgow prognostic score. Urol Int 107(5):489\u2013495","journal-title":"Urol Int"},{"issue":"5","key":"4389_CR38","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.21873\/invivo.12565","volume":"35","author":"T Nagai","year":"2021","unstructured":"Nagai T et al (2021) Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma. In Vivo 35(5):2793\u20132800","journal-title":"In Vivo"},{"issue":"3","key":"4389_CR39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.euo.2023.11.005","volume":"7","author":"J Saal","year":"2024","unstructured":"Saal J et al (2024) On-treatment Modified Glasgow prognostic score provides predictive information complementary to radiological staging in metastatic urothelial carcinoma on immunotherapy. Eur Urol Oncol 7(3):328\u2013331","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"4389_CR40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2023.1822","volume":"9","author":"J Saal","year":"2023","unstructured":"Saal J et al (2023) Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA Oncol 9(8):1048\u20131055","journal-title":"JAMA Oncol"},{"issue":"34","key":"4389_CR41","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794\u20139","journal-title":"J Clin Oncol"},{"issue":"13","key":"4389_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15133339","volume":"15","author":"P Jarmuzek","year":"2023","unstructured":"Jarmuzek P et al (2023) Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 15(13):1","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4389_CR43","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1245\/s10434-021-10988-x","volume":"29","author":"CM Lorton","year":"2022","unstructured":"Lorton CM et al (2022) C-reactive protein and C-Reactive protein-based scores to predict survival in esophageal and junctional adenocarcinoma: systematic review and meta-analysis. Ann Surg Oncol 29(3):1853\u20131865","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4389_CR44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12885-021-09108-5","volume":"22","author":"A Winther-Larsen","year":"2022","unstructured":"Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B (2022) Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients. BMC Cancer 22(1):63","journal-title":"BMC Cancer"},{"issue":"20","key":"4389_CR45","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M et al (2023) Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS Trial. J Clin Oncol 41(20):3595\u20133607","journal-title":"J Clin Oncol"},{"issue":"12","key":"4389_CR46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889\u2013895","journal-title":"Prostate"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04389-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:02:17Z","timestamp":1767477737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04389-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4389"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04389-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to a retrospective Open Access order.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FW would like to declare that he advises for AdonHealth, Astellas, AstraZeneca and Johnsen & Johnson outside the scope of the submitted work. The other authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}